Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast

The number of treatment options continues to increase in the T1D space. Existing agents fail to provide sustained and intrinsic control of T1D, and none address the autoimmune component of T1D’s etiology. The emphasis has shifted on the types of therapies in development for T1D, with a significant interest in immune modulation and cell-based therapies. The launch of biosimilar insulins is creating pricing pressure on branded originators in the major markets and giving payers greater leverage to negotiate price.

QUESTIONS ANSWERED

  • How will endocrinologists differentiate between the emerging therapies, and which agents will enjoy the greatest clinical and commercial success in an increasingly stringent regulatory and cost-sensitive environment?
  • What impact will the increasing use of insulin pumps have on market dynamics?
  • What will be the market impact of biosimilar insulins? How resistant are physicians to payer pressure to switch patients to biosimilar insulin?
  • What role will SGLT inhibitors and immunomodulators play in the evolving T1D treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Type 1 Diabetes - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Type 1 Diabetes - Key Findings - December 2019
      • Key Updates
        • September 2020
          • December 2019
            • September 2019
              • June 2019
                • March 2019
                • Market Outlook
                  • Key Findings
                    • Market Share of Drug Classes for Type 1 Diabetes: 2018
                    • Market Share of Drug Classes for Type 1 Diabetes: 2028
                    • Type 1 Diabetes SWOT Analysis
                  • COVID-19: Areas of Potential Forecast Impact
                    • Market Drivers and Constraints
                      • What Factors Are Driving the Market for Type 1 Diabetes?
                      • What Factors Are Constraining the Market for Type 1 Diabetes?
                      • T1D Sales and Patient Share by Drug Class: Major Markets 2018-2028
                      • T1D Patient Share of Insulins Split by Brand / Biosimilar: Major Markets 2018-2028
                    • Drug-Class Specific Trends
                      • Long-acting Insulins
                      • T1D Sales and Patient Share for Long-acting Insulins: Adult Population, Major Markets 2018-2028
                      • Rapid-acting Insulins
                      • T1D Sales and Patient Share for Rapid-acting Insulin: Adult Population, Major Markets 2018-2028
                      • T1D Sales and Patient Share for SGLT Inhibitors: Adult Population, Major Markets 2018-2028
                      • T1D Sales and Patient Share for Teplizumab: United States, Adult and Child Populations, 2018-2028
                  • Forecast
                    • Market Forecast Assumptions - Type 1 Diabetes 2018-2028 - December 2019
                    • Market Forecast Dashboard - Type 1 Diabetes 2018-2028 - December 2019
                  • Etiology and Pathophysiology
                    • Disease Overview
                      • Etiology
                        • Risk Factors for Type 1 Diabetes
                      • Pathophysiology
                        • Type 1 Diabetes: How the Disease Might Arise
                      • Natural History
                        • Key Pathways and Drug Targets
                          • Summary of Type 1 Diabetes Drug Targets
                      • Epidemiology Overview
                        • Key Findings
                          • Epidemiology Populations
                            • Disease Definition
                            • Methods
                            • Sources Used for Diagnosed Prevalence Estimates of Type 1 Diabetes
                            • Diagnosed Prevalent Cases of Type 1 Diabetes : 2018-2028 (thousands)
                            • Drug-Treated Prevalent Cases of Type 1 Diabetes: 2018-2028
                        • Current Treatment
                          • Key Findings
                            • Treatment Goals
                              • Key Endpoints Used in Clinical Trials for Type 1 Diabetes
                            • Key Current Therapies
                              • Overview
                              • Mechanism of Action of Key Current Drugs Used for Type 1 Diabetes
                              • Current Treatments Used for Type 1 Diabetes
                              • Glargine U100
                              • Advantages and Disadvantages of Glargine U100
                              • Ongoing Clinical Development of Glargine U100
                              • Expert Insight: Glargine U100
                              • Detemir
                              • Advantages and Disadvantages of Detemir
                              • Ongoing Clinical Development of Detemir
                              • Expert Insight: Detemir
                              • Degludec
                              • Advantages and Disadvantages of Degludec
                              • Ongoing Clinical Development of Degludec
                              • Expert Insight: Degludec
                              • Glargine U300
                              • Advantages and Disadvantages of Glargine U300
                              • Ongoing Clinical Development of Glargine U300
                              • Expert Insight: Glargine U300
                              • Aspart
                              • Advantages and Disadvantages of Aspart
                              • Ongoing Clinical Development of Aspart
                              • Expert Insight: Aspart
                              • Glulisine
                              • Advantages and Disadvantages of Glulisine
                              • Ongoing Clinical Development of Glulisine
                              • Expert Insight: Glulisine
                              • Lispro
                              • Advantages and Disadvantages of Lispro
                              • Ongoing Clinical Development of Lispro
                              • Expert Insight: Lispro
                              • Technosphere
                              • Advantages and Disadvantages of Technosphere
                              • Ongoing Clinical Development of Technosphere
                              • Expert Insight: Technosphere
                              • Ultra-Rapid Aspart
                              • Advantages and Disadvantages of Ultra-Rapid Aspart
                              • Ongoing Clinical Development of Ultra-Rapid Aspart
                              • Expert Insight: Ultra-Rapid Aspart
                              • Regular Insulin
                              • Advantages and Disadvantages of Regular Insulin
                              • NPH Insulin
                              • Advantages and Disadvantages of NPH Insulin
                              • Premixed Insulin
                              • Advantages and Disadvantages of Premixed Insulins
                              • Expert Insight: Premixed Insulin
                              • Dapagliflozin
                              • Advantages and Disadvantages of Dapagliflozin
                              • Ongoing Clinical Development of Dapagliflozin
                              • Expert Insight: Dapagliflozin
                              • Ipragliflozin
                              • Advantages and Disadvantages of Ipragliflozin
                              • Ongoing Clinical Development of Ipragliflozin
                              • Expert Insight: Ipragliflozin
                              • Pramlintide
                              • Advantages and Disadvantages of Pramlintide
                              • Ongoing Clinical Development of Pramlintide
                              • Expert Insight: Pramlintide
                            • Medical Practice
                              • Overview
                              • Country-Specific Treatment Guidelines for Type 1 Diabetes
                              • Factors Influencing Drug Selection in Type 1 Diabetes
                              • Generalized Treatment Decision Tree for Type 1 Diabetes: Major Markets
                          • Unmet Need Overview
                            • Current and Future Attainment of Unmet Needs in Type 1 Diabetes
                            • Top Unmet Needs in Type 1 Diabetes: Current and Future Attainment
                          • Emerging Therapies
                            • Key Findings
                              • Pipeline Trends in Type 1 Diabetes
                            • Key Emerging Therapies
                              • Key Therapies in Development for Type 1 Diabetes
                              • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Type 1 Diabetes
                              • Ultra-Rapid Lispro Profile
                              • Analysis of the Clinical Development Program for Ultra-Rapid Lispro
                              • Expert Insight: Ultra-Rapid Lispro
                              • Expectations for Launch and Sales Opportunity of Ultra-Rapid Lispro in Type 1 Diabetes
                              • Empagliflozin Profile
                              • Analysis of the Clinical Development Program for Empagliflozin
                              • Expert Insight: Empagliflozin
                              • Expectations for Launch and Sales Opportunity of Empagliflozin in Type 1 Diabetes
                              • Sotagliflozin Profile
                              • Analysis of the Clinical Development Program for Sotagliflozin
                              • Expert Insight: Sotagliflozin
                              • Expectations for Launch and Sales Opportunity of Sotagliflozin in Type 1 Diabetes
                              • Teplizumab Profile
                              • Analysis of the Clinical Development Program for Teplizumab
                              • Expert Insight: Teplizumab
                              • Expectations for Launch and Sales Opportunity of Teplizumab in Type 1 Diabetes
                            • Early-Phase Pipeline Analysis
                              • Select Compounds in Phase II Development for Type 1 Diabetes
                          • Access & Reimbursement Overview
                            • Region-Specific Reimbursement Practices
                              • Key Market Access Considerations in Type 1 Diabetes: United States
                              • General Reimbursement Environment: United States
                              • Key Market Access Considerations in Type 1 Diabetes: EU5
                              • General Reimbursement Environment: EU5
                              • Key Market Access Considerations in Type 1 Diabetes: Japan
                              • General Reimbursement Environment: Japan
                            • Looking for More?
                          • Appendix
                            • Key Abbreviations Related to Type 1 Diabetes
                            • Brands, Marketers, and Generic Availability of Key Therapies for Type 1 Diabetes: by Market
                            • Type 1 Diabetes Bibliography